ARVN

Arvinas Inc.

Price

$9.68

return (12m)

35.57%

p/e

61.72

p/bv

1.02

DIVIDEND YIELD

0.00%

ARVN price

Arvinas

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment ARVN

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

19.21%

3 months

6.37%

1 year

35.57%

2 years

-61.96%

5 years

-88.72%

10 years

0.00%

Asset Comparator

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Fundamentals ARVN

Valuation

P/E

61.72

Sector -2.19

Industry 1.21

P/BV

1.02

Sector 2.22

Industry 2.11

P/Revenue (PSR)

1.81

Sector 2.01

Industry 0.78

EV/EBITDA

0.04

Sector -17.81

Industry -25.30

EV/EBIT

0.04

Sector -26.72

Industry -18.04

P/EBITDA

-43.15

Sector 0.36

Industry 0.18

P/EBIT

-31.71

Sector -3.34

Industry 1.26

P/Total Assets

0.85

Sector 1.23

Industry 0.86

P/Net Current Assets

1.06

Sector -27.35

Industry -12.37

P/Working Capital

1.01

Sector -4.54

Industry -49.48

EPS

0.14

Sector -0.87

Industry -0.55

BVPS

8.65

Sector 3.80

Industry 5.36

Efficiency

Gross Margin

100.00%

Sector 43.36%

Industry 31.53%

EBITDA Margin

66.20%

Sector -323.65%

Industry -73.39%

EBIT Margin

65.72%

Sector -194.57%

Industry -11.94%

Operating Margin

-5.72%

Sector -24.37%

Industry -9.87%

Net Profit Margins

2.94%

Sector -28.88%

Industry -19.76%

Asset Turnover

0.37

Sector 0.12

Industry 0.22

Profitability

ROE

1.65%

Sector -33.82%

Industry -37.56%

ROA

1.38%

Sector -29.63%

Industry -17.56%

ROIC

952.23%

Sector -431.16%

Industry -111.59%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

0.00%

Sector -

Industry -

Debt

Current Ratio

7.91

Sector 1.84

Industry 1.14

Net Debt / EBITDA

-3.43

Sector -1.47

Industry -31.86

Net Debt / EBIT

-3.46

Sector -1.32

Industry 2.06

Net Debt / Equity

-1.01

Sector -0.35

Industry 0.14

Gross Debt / Equity

0.00

Sector 0.14

Industry 0.51

Equity/Assets

0.83

Sector 0.42

Industry 0.25

Liabilities/Assets

0.17

Sector 0.46

Industry 0.46

Growth

5Y Revenue CAGR

42.71%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Arvinas ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$9.68

Fair Value

$5.22

Upside Return potential.

-46.08%

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ARVN

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
ARVN Arvinas Inc.	$9.68	35.01%	0.00%	61.72	1.02	1.65%	2.94%
LLY Eli Lilly and Compay	$1,280.34	83.05%	0.54%	39.62	31.24	78.84%	33.53%
ISRG Intuitive Surgical Inc.	$397.72	-17.36%	0.00%	45.09	7.73	17.15%	28.45%
SNY Sanofi	$45.83	-4.42%	4.04%	7.10	1.31	18.43%	13.81%
NVS Novartis AG	$160.31	31.78%	2.05%	22.57	6.87	30.41%	22.50%
TMO Thermo Fisher Scientific Inc.	$613.54	26.39%	0.30%	31.58	4.17	13.19%	15.04%
ABT Abbott Laboratories	$114.43	-11.62%	2.33%	33.60	3.57	10.61%	11.65%
MDT Medtronic PLC	$94.13	4.71%	3.10%	24.50	2.35	9.59%	13.20%
GSK GlaxoSmithKline PLC	$52.88	41.51%	3.59%	15.15	4.28	28.24%	14.54%
CVS CVS Health Corporation	$93.65	37.68%	2.73%	25.48	1.56	6.12%	1.18%
BSX Boston Scientific Corp.	$52.01	-49.87%	0.00%	18.98	0.00	-%	19.57%
TMDX TransMedics Group Inc.	$93.97	-25.21%	0.00%	20.36	5.96	29.28%	22.69%
IDXX IDEXX Laboratories Inc.	$562.20	-11.86%	0.00%	38.32	27.08	70.67%	25.03%
RMD ResMed Inc.	$230.65	-18.34%	1.07%	21.40	4.95	23.13%	26.94%
DHR Danaher Corporation	$211.50	0.79%	0.71%	35.81	2.73	7.61%	15.95%
HCA HCA Healthcare Inc.	$407.05	4.09%	0.74%	13.12	-27.97	-213.15%	8.77%
COHR Coherent Inc.	$287.47	217.68%	0.00%	79.32	5.68	7.16%	11.31%
PHG Koninklijke Philips NV	$27.62	4.58%	3.70%	20.19	1.98	9.80%	6.30%
SYK Stryker Corp.	$339.98	-9.77%	1.02%	34.97	5.44	15.55%	14.43%
INMD InMode Ltd.	$15.04	5.14%	0.00%	11.54	1.42	12.32%	20.69%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

ARVN Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Arvinas

Arvinas Inc.

Average Investor10 user rating

4.0 (1 people)

United States

13 years

Founded: 2013

2018

Time since IPO - 8 years

179

Employees

Arvinas Inc. (United States) is listed on the Nasdaq and has a market capitalization of $573.95 million, with shareholders equity totaling $562.10 million.

The company employs approximately 179 people and operates in the Health sector, within the Pharmaceutical Products industry.

Over the past 12 months, Arvinas Inc. reported $316.70 million in revenue, generating net income of $9.30 million.

Key financial metrics include a P/E ratio of 61.72, a price-to-book (P/B) ratio of 1.02, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker ARVN.

Market cap

$573.95 million

Net worth

$562.10 million

$562,100,000.00

Assets

$675.10 million

$675,100,000.00

Total Shares Outstanding

65.00 million

65,000,000

Average Daily Trading Volume

$817.17 Thousand

$817,166.00

Sector

Health

Industry

Pharmaceutical Products

ARVN

ARVN revenue and profits

Financial Results ARVN

DRAG THE FRAME TO SEE MORE DATA

ARVN cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

CVS - CVS Health

$93.65 36,41% (12M)

P/E

25.48

2.73%

ROE

6.12%

P/BV

1.56

CI - Cigna

$277.45 --6,37% (12M)

P/E

10.82

2.19%

ROE

16.04%

P/BV

1.74

CNC - Centene

$64.69 120,03% (12M)

P/E

-6.48

0.00%

ROE

-22.51%

P/BV

1.46

HUM - Humana

$378.02 32,24% (12M)

P/E

36.20

0.92%

ROE

6.63%

P/BV

2.40

SNY - Sanofi

$45.83 --5,73% (12M)

P/E

7.10

4.04%

ROE

18.43%

P/BV

1.31

LLY - Eli Lilly

$1,280.34 81,92% (12M)

P/E

39.62

0.54%

ROE

78.84%

P/BV

31.24

HCA - HCA Healthcare

$407.05 --0,11% (12M)

P/E

13.12

0.74%

ROE

-213.15%

P/BV

-27.97

NVS - Novartis

$160.31 28,43% (12M)

P/E

22.57

2.05%

ROE

30.41%

P/BV

6.87